CS585 / Cereno Scientific, University of Michigan - LARVOL DELTA

CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists (ASH 2023) - "CS585 and other IP receptor agonists, iloprost and selexipag, were assessed by direct comparison to elucidate potential differences in selectivity and sustained action. Importantly, CS585 does not affect coagulation parameters and previous studies demonstrated no potential for increased bleeding in mouse models. Overall, CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP receptor on platelets for primary inhibition of thrombosis with a reduced risk of bleeding."

Preclinical • Cardiovascular • Hematological Disorders • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombosis

Selectivity and Long Action of In Vivo Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis (ASH 2024) - "In both in vivo and ex vivo models, we observe non-selective effects of iloprost and selexipag, in addition to confirming the limitations of length of effect in the blood previously reported in the literature. In overcoming the concerns of sustained efficacy in the blood while maintaining high selectivity for the IP receptor, CS585 represents a novel approach for the anti-platelet treatment of thrombotic diseases, with the potential to augment the therapeutic options for patients suffering from diseases like thrombosis, VTE, MI, stroke, and PAH."

Preclinical • Cardiovascular • Hematological Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases • Thrombosis

Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential (AHA 2024) - "We sought to assess the anti-thrombotic efficacy and pharmacodynamic stability of IP agonists CS585, iloprost and selexipag, in both ex vivo and in vivo models.We evaluated the timeframe of effect of CS585, iloprost, and selexipag in mice following a single IV dose. Our results suggest that CS585, a novel IP receptor agonist, sustainably inhibits platelet activation and clot formation for extended periods, in contrast to existing alternatives. This demonstrates a significant improvement in the pharmacodynamic effects of IP receptor agonists in the blood, highlighting CS585 as a novel anti-platelet therapeutic with the potential to treat thrombotic diseases."

Clinical • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis